Researchers from the Australian Mater Medical Research Institute, the University of Brisbane and U.S. biotech company GlycoMimetics Inc. have reported new insights into how blood stem cells are activated by selectins, and how blocking that activation may be able to protect them from the effects of chemotherapy and radiation.